logo_tau.png
Alpha Tau Announces Multiple Corporate Updates Ahead of 2022 Annual Meeting of the American Society for Radiation Oncology
21 oct. 2022 16h01 HE | Alpha Tau Medical Ltd.
- Medicines and Healthcare products Regulatory Agency of the United Kingdom approves clinical trial in squamous cell carcinoma of the vulva at Addenbrookes Hospital in Cambridge - - Health Canada...
AMR Logo.png
Global Bone Cancer Treatment Market to Reach $1.8 Billion by 2031: Says AMR
21 oct. 2022 08h51 HE | Allied Market Research
Portland, OR, Oct. 21, 2022 (GLOBE NEWSWIRE) -- According to the report published by Allied Market Research, the global Bone Cancer Treatment Market was estimated at $1.2 billion in 2021 and is...
TVAX Biomedical Announces Receipt of $2 Million FDA Orphan Products Grant for Glioblastoma Study
18 oct. 2022 10h07 HE | TVAX Biomedical
OLATHE, Kan., Oct. 18, 2022 (GLOBE NEWSWIRE) -- TVAX Biomedical (TVAX) is a cancer immunotherapy company that is moving into its pivotal glioblastoma study for FDA regulatory approval. In September...
EvolveImmune Logo.jpg
EvolveImmune Therapeutics to Present New Preclinical Data from Novel Costimulatory T Cell Engager Platform at Upcoming Scientific Conferences
18 oct. 2022 07h00 HE | EvolveImmune
EVOLVE™ Platform Shows Promise as a Differentiated T Cell Costimulation Approach for the Treatment of Solid and Hematological Malignancies Poster Presentations Scheduled for American Association...
NKGen Biotech RGB small.jpg
NKGen Biotech Receives IND Clearance from FDA for SNK02 Allogeneic Natural Killer Cell Therapy for Solid Tumors
17 oct. 2022 14h27 HE | NKGen Biotech
SANTA ANA, Calif., Oct. 17, 2022 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc., a biotechnology company harnessing the power of the body’s immune system through the development of natural killer (NK) cell...
ImmunOs Therapeutics Appoints Dr. Hilmar Ebersbach as Vice President Antibody Development and Protein Engineering
17 oct. 2022 04h00 HE | AKAMPION
- Former Novartis director brings significant expertise in drug discovery and development Schlieren (Zurich Area), Switzerland, and Gaithersburg, MD, USA – October 17, 2022 – ImmunOs Therapeutics...
PDS Biotech Logo.png
PDS Biotech to Host Head and Neck Cancer KOL Roundtable on October 26, 2022
12 oct. 2022 08h00 HE | PDS Biotechnology Corporation
FLORHAM PARK, N.J., Oct. 12, 2022 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB),  a clinical-stage immunotherapy company developing a growing pipeline of targeted immunotherapies...
logo 600X600.png
Global Non-small Cell Lung Cancer Treatment Market to Surpass US$ 50,962.7 Million by 2030, Says Coherent Market Insights (CMI)
11 oct. 2022 09h15 HE | CMI
Seattle, Oct. 11, 2022 (GLOBE NEWSWIRE) -- According to Coherent Market Insights, the global non-small cell lung cancer treatment market is estimated to be valued at US$ 24,910.7 million in 2022 and...
PDS Biotech Logo.png
PDS Biotech Announces Expanded Interim Data in PDS0101 Triple Combination Phase 2 Trial Targeting Advanced HPV-Positive Cancers
11 oct. 2022 08h00 HE | PDS Biotechnology Corporation
FLORHAM PARK, N.J., Oct. 11, 2022 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted immunotherapies...
Immatics Announces $110 Million Underwritten Offering of Ordinary Shares
10 oct. 2022 07h37 HE | https://immatics.com/
Houston, Texas and Tuebingen, Germany, October 10, 2022 – Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T...